Processa Pharmaceuticals Stock Pattern Recognition High Wave Candle
| PCSA Stock | USD 2.76 -0.12 -4.17% |
| Symbol |
Recognition |
The output start index for this execution was ten with a total number of output elements of fifty-one. The function generated a total of nine valid pattern recognition events for the selected time horizon. The High-Wave Candle may signal Processa Pharmaceuticals market turn when observed in several bundles.
Processa Pharmaceuticals Technical Analysis Modules
Most technical analysis of Processa Pharmaceuticals help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Processa from various momentum indicators to cycle indicators. When you analyze Processa charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. The company was incorporated in 2011 and is based in Hanover, Maryland. Processa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people. Liquidity and trading activity can influence how quickly new information is reflected in Processa Pharmaceuticals's price. Lower trading activity may introduce occasional variability in execution conditions. Processa Pharmaceuticals has a market cap of 6.68 M, ROE of -2.71%.
Methodology
Unless otherwise specified, financial data for Processa Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Processa (USA Stocks:PCSA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Processa Pharmaceuticals may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardSome investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Processa Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Processa Pharmaceuticals' short interest history, or implied volatility extrapolated from Processa Pharmaceuticals options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Artificial Intelligence Invested few shares | |
 | Momentum Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Driverless Cars Invested few shares | |
 | Hedge Favorites Invested few shares | |
 | Macroaxis Picks Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Advertising Invested few shares | |
 | FinTech Invested over 20 shares | |
 | Data Storage Invested few shares |
More Resources for Processa Stock Analysis
Reviewing Processa Pharmaceuticals commonly begins with financial statements and performance trends. Ratios and trend metrics help frame Processa Pharmaceuticals' operating context. Outlined below are key reports that provide context for Processa Pharmaceuticals Stock:Processa Pharmaceuticals has a market cap of 6.68 M, ROE of -2.71%. Your Equity Center can help frame allocation decisions. The allocation includes a position in Processa Pharmaceuticals within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To understand the process of investing in Processa Stock, visit our How to Invest in Processa Pharmaceuticals guide.Analysis related to Processa Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Investors evaluate Processa Pharmaceuticals using market value and book value, each describing different facets of the business. Processa Pharmaceuticals' market capitalization is 6.68 M. A P/B ratio of 1.15 indicates the market values Processa Pharmaceuticals above its accounting book value. Enterprise value stands at 375.6 K. Value and price for Processa Pharmaceuticals are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
Value and price for Processa Pharmaceuticals are related but not identical, and they can diverge across cycles. For Processa Pharmaceuticals, key inputs include a P/B ratio of 1.15, and ROE of -2.71%. Market price reflects the current exchange level formed by active bids and offers.